ERBB2 and urinary bladder cancer: The novelty of our previous article published 2005 was to show the high percentage of HER2 expression in urinary bladder cancers and to indicate a possible value of HER2-targeted therapy (with for example lapatinib and/or trastuzumab).22 However, since then there has been reports on resistance of urinary bladder cancer for both EGFR-and HER2-targeting agents (e.g. cetuximab, trastuzumab, lapatinib).5–8 The novelty of the present article is to suggest targeting of the receptors with agents9–12 that deliver radionuclides of therapy interest.